🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

624 results for “Solid” Clear

  1. EIK1004-001 (IMP1707-001)

    Eikon Therapeutics

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  2. EIK1005

    Eikon Therapeutics

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  3. EIK1005 10mg Tablets, EIK1005 50mg Tablets, PEMBROLIZUMAB , EIK1005 200mg Tablets

    Eikon Therapeutics

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  4. Ensartinib

    First Tracks Biotherapeutics

    Solid Tumors

    phase 2 small molecule active

    1 trial

  5. Erlotinib

    Solid Biosciences

    Leptomeningeal Carcinomatosis

    phase 2 small molecule terminated

    1 trial

  6. Etigilimab

    Mereo BioPharma Group plc

    Solid Tumor, Adult

    phase 2 small molecule completed

    1 trial

  7. Fianlimab, LIBTAYO 350 mg concentrate for solution for infusion.

    Disc Medicine

    Metastatic solid tumors, these may include but are not limited to melanoma, non-small-cell lung carcinoma (NSCLC), cervical cancer, microsatellite instable (MSI)-high/deficient mismatch repair (dMMR) cancer, renal cell carcinoma (RCC), CSCC, urothelial cell carcer (UCC), small cell lung cancer (SCLC) and head and neck squamous cell carcinoma (HNSCC).

    phase 2 small molecule active

    1 trial

  8. Futibatinib, Tecentriq 1 200 mg concentrate for solution for infusion, JNJ-61186372

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Subjects with advanced solid tumour

    phase 2 small molecule active

    1 trial

  9. GEN1042 DP, PEMBROLIZUMAB

    Genmab A/S

    Metastatic Solid Malignant tumors

    phase 2 small molecule active

    1 trial

  10. GEN1047 DP

    Genmab A/S

    Malignant Solid Tumors

    phase 2 small molecule active

    1 trial

  11. GEN1078 DP

    Genmab A/S

    Malignant solid tumors

    phase 2 small molecule active

    1 trial

  12. GVA + HDAC Consolidation & Gilteritinib Maintenance

    First Tracks Biotherapeutics

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  13. Gemcitabine 100 mg/ml Concentrate for Solution for Infusion, 9-ING-41, Abraxane 5 mg/ml powder for dispersion for infusion.

    ACTUATE THERAPEUTICS, INC.

    Refractory Hematologic Malignancies or Solid Tumors

    phase 2 small molecule active

    1 trial

  14. HEC169096

    Sunshine Biopharma

    Advanced Solid Tumor

    phase 2 small molecule active

    1 trial

  15. IAH0968

    China SXT Pharmaceuticals

    Advanced Solid Tumor

    phase 2 mab active

    1 trial

  16. IMFINZI 50 mg/mL concentrate for solution for infusion.

    Cancer Prevention Pharma (Ireland) Limited

    Patients with locally advanced or metastatic solid tumours

    phase 2 small molecule active

    1 trial

  17. IMFINZI 50 mg/mL concentrate for solution for infusion., IMJUDO 20 mg/ml concentrate for solution for infusion.

    AstraZeneca AB

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  18. IMP1734

    Eikon Therapeutics

    Advanced Solid Tumor

    phase 2 small molecule active

    1 trial

  19. IMX-110 combined with Tislelizumab

    Immix Biopharma

    Advanced Solid Tumor

    phase 2 small molecule active

    1 trial

  20. INAVOLISIB, RO 743-5846/F04, RO7223619, INAVOLISIB, RO 743-5846/F07, Ipatasertib, Rozlytrek 200 mg hard capsules, Alecensa 150 mg hard capsules, Rozlytrek 100 mg hard capsules, Tecentriq 1 200 mg concentrate for solution for infusion, INAVOLISIB, Rozlytrek, Ipatasertib, Camonsertib, INAVOLISIB, RO 749-9790/F02-02

    Roche Registration Limited

    Solid tumors

    phase 2 small molecule active

    1 trial

  21. INBRX-106 - Hexavalent OX40 agonist antibody

    Inhibrx Biosciences

    Solid Tumor

    phase 2 small molecule active

    1 trial

  22. INCB099280, Adagrasib

    Incyte Biosciences Distribution B.V.

    Advanced Solid Tumors Harboring a KRASG12C Mutation

    phase 2 small molecule active

    1 trial

  23. IPN01195, IPN01195

    Ipsen Pharma

    Advanced Solid Tumour

    phase 2 small molecule active

    1 trial

  24. IPN01203

    Ipsen Pharma

    Advanced Solid Tumor, Metastatic Solid Tumor

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources